These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9336357)

  • 1. Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum.
    De Lena M; Lorusso V; Bottalico C; Brandi M; De Mitrio A; Catino A; Guida M; Latorre A; Leone B; Vallejo C; Gargano G
    J Clin Oncol; 1997 Oct; 15(10):3208-13. PubMed ID: 9336357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between HPLC-determined lonidamine serum levels and clinical response in patients with advanced ovarian cancer.
    Bottalico C; Lorusso V; Brandi M; Micelli G; Rella CA; Coviello M; Atlante AM; Quaranta M; De Lena M
    Anticancer Res; 1996; 16(6B):3865-9. PubMed ID: 9042272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carboplatin plus ifosfamide as salvage treatment of epithelial ovarian cancer: a pilot study.
    Lorusso V; Catino A; Leone B; Rabinovich M; Gargano G; Paradiso A; De Lena M
    J Clin Oncol; 1993 Oct; 11(10):1952-6. PubMed ID: 8410121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study.
    De Lena M; Lorusso V; Latorre A; Fanizza G; Gargano G; Caporusso L; Guida M; Catino A; Crucitta E; Sambiasi D; Mazzei A
    Eur J Cancer; 2001 Feb; 37(3):364-8. PubMed ID: 11239758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design.
    Berruti A; Bitossi R; Gorzegno G; Bottini A; Alquati P; De Matteis A; Nuzzo F; Giardina G; Danese S; De Lena M; Lorusso V; Farris A; Sarobba MG; DeFabiani E; Bonazzi G; Castiglione F; Bumma C; Moro G; Bruzzi P; Dogliotti L;
    J Clin Oncol; 2002 Oct; 20(20):4150-9. PubMed ID: 12377958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.
    Soulié P; Bensmaïne A; Garrino C; Chollet P; Brain E; Fereres M; Jasmin C; Musset M; Misset JL; Cvitkovic E
    Eur J Cancer; 1997 Aug; 33(9):1400-6. PubMed ID: 9337681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: a multicenter randomized clinical trial.
    Ianniello GP; De Cataldis G; Comella P; Scarpati MD; Maiorino A; Brancaccio L; Cioffi R; Lombardi A; Carnicelli P; Tinessa V
    Cancer; 1996 Jul; 78(1):63-9. PubMed ID: 8646728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined carboplatin plus ifosfamide and cisplatin in patients with advanced ovarian carcinoma. A phase I-II study. GOCS (Gynecological Oncology Cooperative Study).
    Lorusso V; Leone B; Di Vagno G; Manzione L; Palmeri S; Vallejo C; Machiavelli M; Nacci G; Bilancia D; Leonardi V; Catino A; Gargano G; Loverro G; Selvaggi L; De Lena M
    Gynecol Oncol; 1998 Feb; 68(2):172-7. PubMed ID: 9514802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy and lonidamine in advanced non-small cell lung cancer.
    Buccheri G; Ferrigno D; Rosso A
    Cancer; 1993 Sep; 72(5):1564-72. PubMed ID: 8394198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-line chemotherapy with cisplatin-ifosfamide in patients with ovarian cancer previously treated with carboplatin-cyclophosphamide.
    Polyzos A; Tsavaris N; Kosmas C; Petrikos G; Giannikos L; Kalahanis N; Papadopoulos O; Christodoulou K; Giannakopoulos K; Veslemes M; Katsilambros N
    J Chemother; 1999 Apr; 11(2):144-9. PubMed ID: 10326746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin and epirubicin plus oral lonidamine as first-line treatment for metastatic breast cancer: a phase II study of the Southern Italy Oncology Group (GOIM).
    Gebbia V; Borsellino N; Testa A; Latteri MA; Milia V; Valdesi M; Giotta F; Gebbia N; Colucci G
    Anticancer Drugs; 1997 Nov; 8(10):943-8. PubMed ID: 9436637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation by lonidamine on the combined activity of cisplatin and epidoxorubicin in human breast cancer cells.
    Silvestrini R; Gornati D; Zaffaroni N; Bearzatto A; De Marco C
    Breast Cancer Res Treat; 1997 Jan; 42(2):103-12. PubMed ID: 9138599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer.
    Lund B; Hansen OP; Hansen HH; Hansen M
    Semin Oncol; 1992 Feb; 19(1 Suppl 1):26-9. PubMed ID: 1411618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.
    Bookman MA; Malmström H; Bolis G; Gordon A; Lissoni A; Krebs JB; Fields SZ
    J Clin Oncol; 1998 Oct; 16(10):3345-52. PubMed ID: 9779711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitomycin C and lonidamine as second-line treatment of advanced colorectal cancer patients.
    Maiello E; Giotta F; Gebbia V; Testa A; Galetta D; Riccardi F; Gebbia N; Colucci G
    Anticancer Res; 1996; 16(5B):3177-9. PubMed ID: 8967732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial.
    Dogliotti L; Berruti A; Buniva T; Zola P; Baù MG; Farris A; Sarobba MG; Bottini A; Alquati P; Deltetto F; Gosso P; Monzeglio C; Moro G; Sussio M; Perroni D
    J Clin Oncol; 1996 Apr; 14(4):1165-72. PubMed ID: 8648371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter phase II trial.
    Potamianou A; Androulakis N; Papakotoulas P; Toufexi H; Latoufis C; Kouroussis C; Christofilakis C; Xenidis N; Georgoulias V; Polyzos A
    Oncology; 2005; 69(4):348-53. PubMed ID: 16293974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised trial of MACC chemotherapy with or without lonidamine in advanced non-small cell lung cancer. Cuneo Lung Cancer Study Group (CuLCaSG).
    Buccheri G; Ferrigno D
    Eur J Cancer; 1994; 30A(10):1424-31. PubMed ID: 7833096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Covens A; Blessing J; Bender D; Mannel R; Morgan M;
    Gynecol Oncol; 2006 Mar; 100(3):586-90. PubMed ID: 16249022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.